Page 2 THE MALDEN ADVOCATE–Friday, February 21, 2025 Maldonians running for the Dana-Farber Marathon Challenge team Raising funds for cancer research at Dana-Farber Special to The Advocate O n April 21, two Malden residents, Michael Bryant and Laura Stucchi, are running to defy cancer as a member of the Dana-Farber Marathon Challenge (DFMC) team in the 129th Boston Marathon®: Along with more than 500 DFMC teammates from across the United States and around Need a hall for your special event? The Schiavo Club, located at 71 Tileston Street, Everett is available for your Birthdays, Anniversaries, Sweet 16 parties and more? For more info, call (857) 249-7882 8 Norwood St. Everett (617) 387-9810 Open Tues. - Sat. at 4:00 PM Closed Sun. & Mon. Announcing our Classic Specials Dine In Only: * FREE Salad with purchase of Entree, Tuesdays & Wednesdays * Cheese Pizza - Only $10 Catch ALL The Live Sports Action On Our Large Screen TV’s Scan & Follow Us on Facebook! the world, they will run Massachusetts’ historic marathon route from Hopkinton to Boston to collectively raise $8.5 million for cancer research at Dana-Farber Cancer Institute. This year marks the 36th annual running of the DFMC. One hundred percent of the money raised by the DFMC team benefits Dana-Farber’s Claudia Adams Barr Program in Innovative Basic Cancer Research, which supports promising science research in its earliest stages. DFMC has raised more than $132 million for the Barr Program to date. In 1990, Dana-Farber was among the first charity organizations to be recognized by the Boston Athletic Association (B.A.A.), which organizes the Boston Marathon. The DFMC team offers its members extensive fundraising support, training guidance from 1976 Boston Marathon Men’s Open Division Champion Jack Fultz and team training runs. DFMC runners who are not time-qualified for the Boston Marathon receive an invitational entry into the race. Laura Stucchi proudly ran the 2024 Boston-Half Marathon with team Dana-Farber and will join 500 DFMC teammates in April to run the 129th Boston Marathon®. (Courtesy photo) Runners include cancer survivors and patients and family and friends of those who have been affected by cancer. Each team member must fulfill a basic fundraising commitment: • Invitational runners – runners who receive their entry from Dana-Farber have a minimum fundraising commitment of $10,000. • Own entry runners – runners who have joined the DFMC after obtaining their own race entry have a fundraising commitment of $4,000. To contribute to the DFMC, visit RunDFMC.org or contact the DFMC office at 617-6321970 or dfmc@ dfci.harvard.edu. Follow DFMC on Facebook at www.facebook/ marathonchallenge and on X at #RunDFMC. About the Claudia Adams Barr Program in Innovative Basic Cancer Research Since its incepwww.810bargrille.com After running in the 128th Boston Marathon, Michael Bryant will once again join the DFMC team in this year’s marathon to defy cancer. (Courtesy photo) tion in 1990, the DFMC has raised more than $132 million for this program. Dana-Farber Cancer Institute Trustees J. Wayne and Delores Barr Weaver founded the program in 1987 to honor Mrs. Weaver’s mother, Claudia Adams Barr, who had lost her battle with cancer 30 years earlier. About Dana-Farber Cancer Institute Dana-Farber is one of the world’s leading centers of cancer research and treatment. The mission of Dana-Farber is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. Dana-Farber is a federally designated Comprehensive Cancer Center and a teaching affiliate of Harvard Medical School, providing the latest treatments in cancer for adults through Dana-Farber Brigham Cancer Center and for children through Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. Dana-Farber is the only hospital nationwide with a top 4 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care. As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,100 clinical trials.
3 Publizr Home